Author:
Dupont A.,Labrie F.,Cusan L.,Gomez J. L.,Tremblay M.,Lacourcière Y.,Emond J.,Monfette G.
Reference64 articles.
1. Adams JB (1985) Control of secretion and the function of C19-delta-5-steroids of the human adrenal gland. Molec cell Endocr 45:1–17
2. Aseelin J, Mélançon R, Moachon G, Bélanger A (1980) Characteristics of binding to estrogen, androgen, progestin and glucocorticoid receptors in 7,12-dimethylbenz(a)an-thracene-induced mammary tumors and their hormonal control. Cancer Res 40:1612–1622
3. Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD (1988) Total androgen blockade versus castration in metastatic cancer of the prostate. In: Motta M, Serio M (eds), Hormonal Therapy of Prostatic Diseases: Basic and Clincal Aspects, Medicom, Bussum pp 302–311
4. Bélanger A, Dupont A, Labrie F (1984) Inhibition of basai and adrenocorticotropin-stimu-lated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J Clin Endocrinol Metab 59:422–426
5. Bélanger A, Brochu M, Cliche J (1986) Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 62:812–815